Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
HER2+/HR+ Breast Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 1 Participants
N/A N=92 Feedback and Outcomes for Clinically Useful Student Services (FOCUSS)
School-based Mental Health Treatment Services
Primary: Change in Clinician Acceptability of MBC — 3.96; 3.52; 4.54; 3.58 score on a scale
Phase 2 N=19 Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants
Phase 2 N=51 FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Primary: Overall Survival (OS) Rate — 54.2 percentage of patients
N/A N=209 Study of OMNI System in OAG (GEMINI)
Open Angle Glaucoma
Primary: Change in Mean Unmedicated Diurnal IOP — 7.98 mm Hg
Phase 3 N=787 Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population — 37.7; 26.0 percentage of participants…
N/A N=23 Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD
Chronic Musculoskeletal Pain · Posttraumatic Stress Disorder (PTSD) · Mild or Moderate Traumatic Brain Injury
Primary: Change From Baseline: PTSD Checklist-5 (PCL-5) — 15.64 units on a scale — p=.040
N/A N=7 Palliative Care for Persons With ADRD and CI in SNF
Advance Care Planning · Palliative Care · Skilled Nursing Facility
Primary: Number of Participants That Completed Patient Quality of Life Survey — 4; 3; 3; 3 Participants
Phase 2 N=55 To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
Covid19
Primary: Median Time to Sustained Clinical Response — 6; 8 Days
Phase 3 N=941 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT)…
N/A N=2,164 Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities
SARS-CoV-2
Primary: Attendance Rate at Time 2 SARS-CoV-2 Antibody Test — 123; 84; 129; 78 Participants — p=0.003
Phase 2 N=16 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 62; 6; 3 Participants
Phase 1 N=57 Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
Hepatic Impairment
Primary: AUC0-tau, Steady State — 96100; 107000; 103000; 69500 h•ng/mL
Phase 1 N=18 A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
Healthy
Primary: Maximum Serum Concentration(Cmax) for PF-06823859 — 307.4 micrograms/milliliter (ug/mL)